At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed primary intracranial CNS atypical teratoid/rhabdoid tumor (AT/RT)
- ✓Tumor tissue possesses INI-1 gene mutation
- ✓Age 18 years or younger
- ✓Definitive surgical resection of tumor within the past 35 days
- ✕Prior chemotherapy
- ✕Prior radiotherapy
- ✕Other concurrent investigational agents
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor
In Brief
A Phase 2 clinical trial evaluating filgrastim, cisplatin, and 12 other interventions for Central Nervous System Tumor, Pediatric. Completed, enrolled 25 participants across 12 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.